Cipla Receives Final Approval for Generic Sustiva

Cipla Limited announced that it has received final approval for its abbreviated new drug application (ANDA) for Efavirenz Tablets 600 mg from the United States Food and Drug Administration (USFDA). Cipla’s Efavirenz Tablets 600 mg is AB-rated generic therapeutic equivalent version of Bristol-Myers Squibb Pharma Company’s, Sustiva. It is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg. According to IQVIA (IMS Health), Sustiva and its generic equivalents had US sales of approximately USD 105 million for the 12-month period ending April 2018. The product is available for shipping immediately. – Medical Buyer Bureau